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TransplantatABSTRACT
Background. The aim of this study was to evaluate the effects of a single high dose of the
antieT-lymphocyte globulin Fresenius (ATG-F), given before kidney transplantation, on
the prevention of acute rejection response and infections and on the survival rate of the
renal graft and patient.
Methods. Databases including PubMed, Embase, and the Cochrane Library were
searched to identify randomized controlled trials relevant to studying the presurgical use of
a single high dose of ATG-F.
Results. Five RCTs that included 346 patients were selected. The meta-analysis suggested
that the application of ATG-F reduced the postsurgical acute rejection reaction incidence
compared to that of the control group (relative risk ¼ 0.50, 95% conﬁdence interval ¼
0.35e0.71, P ¼ .0001). However, the application of ATG-F exhibited no signiﬁcant effect
on the incidence of urinary tract infection, cytomegalovirus infection, and delayed graft
function. Furthermore, the one-year patient survival rate and kidney graft survival rate
were not affected.
Conclusions. The meta-analysis suggested that the reperfusion use of a single high dose
(9 mg/kg) of ATG-F could effectively reduce the incidence of postsurgical acute rejection
response without affecting the occurrence of infections, the survival rates of kidney grafts
and patients, or the incidence of delayed graft function.Funding: Research Incentive Fund of BeijingChaoyangHospital
Afﬁliated with Capital Medical University (2013D003034000044)
and The Beijing Municipal Administration of Hospitals Clinical
Medicine Development of Special Funding Support
(ZYLX201408).
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100020, China. E-mail: wangwdoctor@126.comACUTE rejection (AR) reaction is one of the mostimportant factors affecting the prognosis of kidney
transplantation. In recent years, researchers have designed
many strategies to reduce the incidence of AR reaction.
Induction therapy has been one of the most prevalent ap-
proaches [1]. The application of polyclonal antibodies has
exhibited a remarkable effect in reducing early rejection
after kidney transplantation. This approach was also shown
to induce immune tolerance and to treat accelerated
rejection and AR reactions [2]. Rabbit anti-human antieT-
lymphocyte globulin Fresenius (ATG-F) is a polyclonal
antibody that targets a human T-lymphocyte antigen. ATG-
F has been widely used in organ transplantation. Previous
studies have found that induction therapy with ATG-F
could signiﬁcantly reduce sensitization and the incidence
of AR response in pediatric transplant recipients, thus
improving the prognosis of kidney transplantation [3,4].Authors. Published by Elsevier Inc. This is an open
le under the CC BY-NC-ND license (http://
mons.org/licenses/by-nc-nd/4.0/).
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ion Proceedings, 48, 2017e2022 (2016)However, other studies have demonstrated that routine in-
duction therapy using ATG-F could result in an over-
suppression of immunity. Although ATG-F reduced the
incidence of AR reaction, it also induced serious side effects
in kidney recipients, such as mortality caused by cardiovas-
cular and infectious events and a signiﬁcantly increased0041-1345/16
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Fig 1. Literature search and ﬁltering process.
2018 DU, WANG, SUN ET ALincidence of advanced-stage malignant tumors [5]. From an
immunological perspective, preventing an immune response
is an easier strategy than terminating an ongoing immune
response. Therefore, Kaden et al proposed a treatment
plan to move the induction therapy of ATG-F from the
postsurgical period to the reperfusion period with a single
high dose [6e8]. In the present study, the Cochrane system
evaluation method was adopted, using a collection of ran-
domized controlled trials (RCTs) to evaluate the effects of a
single high dose (9 mg/kg) of ATG-F before kidney trans-
plantation. Speciﬁcally, the effects of ATG-F on reducing
AR in kidney transplantation and side effects in postsurgical
infections, the survival rates of both the patient and kidney
graft, and delayed graft function (DGF) were assessed. This
study provides reliable evidence for clinical practice in
kidney transplantation.
MATERIALS AND METHODS
The study selection and systematic review were conducted in
accordance with the Preferred Reporting Items for Systematic
Reviews and Meta-analyses (PRISMA) statement. The studies
included were required to meet the following criteria: the study type
was an RCT; the study included a comparison of the efﬁcacy and
safety of ATG-F and placebo; the study subjects were kidney
transplant recipients with no other organ transplantation; and
ATG-F was given as a reperfusion single high dose in the clinical
controlled trials. Studies failed to meet the inclusion were excluded.
Literature Search
The search words “(renal transplantation OR kidney trans-
plantation OR allograft renal transplantation) and (ATG-F OR
ATG-Fresenius OR ATG OR antithymocyte globulin)” were used
with PubMed (1966 to December 2015), Embase (1974- December
2015), and the Cochrane Library (1996 to December 2015). The
searches did not contain a language restriction. Major professional
journals were searched manually in the case of missing retrievals.
Material Extraction and Quality Assessment
Material extracted from the literature search contained the in-
cidences of AR reaction and infections, survival rates of kidney
grafts and patients, and incidences of DGF. A quality assessment
was performed by two of the authors, and the clinical trials were
ﬁltered. Based on conditions such as the use of various randomized
methods, use of blind methods, and lost follow-up data, the quality
of each experiment was assessed, and other data were crosschecked.
Missing data were obtained by contacting the corresponding au-
thors for the clinical trials. Disagreements were resolved through
discussion. The third author was involved whenever required to
resolve disagreements. The quality assessment of the research ar-
ticles, as an evaluation of the methodology of the studies, provided
scores for the various clinical studies based on the Jadad evaluation
scale (maximum of seven points).
Statistical Analysis
RevMan 5.3 software provide by the Cochrane corporate website
was used for the statistical analyses. When the experimental results
showed no heterogeneity, a meta-analysis was performed based on
the choice of a ﬁxed-effect model. When the experimental results
showed heterogeneity, a randomized effect model was used for theanalysis. When the maintenance therapy and the sources of donor
kidney used were not the same in the included trials, a randomized
effect model was used for the analysis. The two categories were
analyzed using the Mantel-Haenszel method. The relative risk (RR)
was calculated, and the 95% conﬁdence interval (95% CI) was
calculated for both categories.RESULTS
Quantity and Quality of the Original Material
The literature ﬁltering process is shown in Fig 1. Initially,
173 papers were found. After reading the title, abstract, or
the full paper, articles that did not meet the inclusion
criteria were excluded. Finally, seven articles were identiﬁed
for the present study, and all of them were English publi-
cations. However, because Samsel et al published three ar-
ticles in 1999, 2001, and 2008 based on the same trial, only
the publication from 2008 was included to avoid duplica-
tion. Therefore, the meta-analysis was performed on a total
of ﬁve English articles that included 346 patients [9e13]. In
these studies, 180 patients received a single high dose of
ATG-F induction therapy, and 166 patients formed control
groups. All of the studies adopted RCT method, and all of
the patients received triple drug maintenance therapy. The
articles that met the quality requirements are shown in
Table 1.
Clinical Trials in the Included Articles and Meta-analysis
Results
Meta-analysis on the Effect of Reperfusion Use of a Single
High Dose of ATG-F on the Incidence of AR. Five articles
met the standards for studying the effect on the incidence of
posttransplantation AR. A total of 346 patients were
included (180 patients in the experimental group and 166
patients in the control group). A random effect model was
used for the analysis. The results of the meta-analysis
showed that the transplantation rejection incidence in the
control group was higher than that in the ATG-F group;
Table 1. Characteristics of the Included Studies
First Author, Year [Ref] Country
Study
Type
Number of
ATG/Non-ATG
ATG-F Dose
and Time Maintenance Immune Therapy
Donor
Characteristics
Quality
Score
Yussim, 2000 [9] Israel RCT 19/19 9 mg/kg, d0 CsAþazathioprineþprednisone NM 4
Kyllonen, 2007 [10] Finland RCT 53/44 9 mg/kg, d0 CsAþazathioprineþprednisolone DCD 7
Samsel, 2008 [11] Poland RCT 40/39 9 mg/kg, d0 CsAþMMFþprednisolone
(MMF converted to azathioprine
after the fourth month)
DCD 6
Sheashaa, 2008 [12] Egypt RCT 40/40 9 mg/kg, d0 Tac/CsAþMMFþprednisolone LRD 7
Van den Hoogen, 2013 [13] Netherlands RCT 28/24 9 mg/kg, d0 TacþMMFþprednisolone DCD 7
Abbreviations: Ref, reference; ATG, anti-T-lymphocyte globulin; ATG-F, ATG-Fresenius; RCT, randomized controlled trial; CsA, cyclosporin A; MMF, mycophenolate
mofetil; Tac, tacrolimus; NM, not mentioned; DCD, death censored donor; LD, living related donor.
SAFETY/EFFICACY OF ATG-F IN KIDNEY TRANSPLANTATION 2019the difference was statistically signiﬁcant. The combined
relative risk (RR) was 0.50, and the 95% CI was 0.35e0.71
(Fig 2). The results suggested that the difference was
statistically signiﬁcant after combining, that is, the
reperfusion use of a single high dose of ATG-F could
signiﬁcantly reduce the incidence of AR in transplantation
compared to that of the control group.
Meta-analysis on the Effect of Reperfusion Use of a Single
High Dose of ATG-F on the Incidence of Urinary Tract
Infection. Five articles met the standards for studying the
effect on the incidence of transplantation urinary tract
infection (UTI), including 180 patients in the experimental
group and 166 patients in the control group. A randomized
effect model was used for the analysis. The results of the
meta-analysis showed that the combined RR value was 1.05
and the 95% CI interval was 0.77e1.42 (Fig 3). The results
suggested that the combined difference had no statistical
signiﬁcance; thus, the reperfusion use of a single high
dose of ATG-F had no obvious effect on the incidence of
UTI compared to that in the control group.
Meta-analysis on the Effect of Reperfusion Use of a Single
High Dose of ATG-F on the Incidence of Cytomegalovirus
Infection. Four articles met the standards for studying the
effect on the incidence of transplantation cytomegalovirus
(CMV) infection. A total of 308 patients were included (161
patients in the experimental group and 147 patients in the
control group). The maintenance therapy and the sources of
donor kidney used were not the same in the included trials.
Therefore, a random effect model was used for the analysis.
The results of the meta-analysis showed that the RRwas 1.46Fig 2. Meta-analysis on the effect of reperfusion use of a single hig
incidence of acute rejection.after combining and the 95% CI was 0.79e2.70 (Fig 4). The
results suggested that the combined difference had no
statistical signiﬁcance; thus, the reperfusion use of a single
high dose of ATG-F had no obvious effect on the
incidence of CMV infection compared to that in the
control group.
Meta-analysis on the Effects of Reperfusion Use of a Single
High Dose of ATG-F on the 1-Year Graft Survival Rate of
Kidney Transplantation. Five articles met the standards for
the effects on the 1-year graft survival rate of kidney
transplantation. A random effect model was used for the
analysis. The results of the meta-analysis showed that the
combined RR was 1.03 and the 95% CI was 0.97e1.09
(Fig 5). The results suggested that the combined
difference had no statistical signiﬁcance; thus, the
reperfusion use of a single high dose of ATG-F had no
obvious effect on the 1-year graft survival rate of kidney
transplantation compared to that in the control group.
Meta-analysis on the Effect of the Reperfusion Use of a
Single High Dose of ATG-F on the 1-Year Patient Survival
Rate. Five articles met the standards for the effects on the
1-year graft survival rate of kidney transplantation. A
random effect model was used for the analysis. The results
of the meta-analysis showed that the combined RR was
1.02 and the 95% CI was 0.98e1.07 (Fig 6). The results
suggested that the combined difference had no statistical
signiﬁcance; therefore, the reperfusion use of a single high
dose of ATG-F had no obvious effect on the 1-year graft
survival rate of kidney transplantation compared to that in
the control group.h dose of antieT-lymphocyte globulin Fresenius (ATG-F) on the
Fig 3. Meta-analysis on the effect of the reperfusion use of a single high dose of antieT-lymphocyte globulin Fresenius (ATG-F) on the
incidence of urinary tract infection.
2020 DU, WANG, SUN ET ALMeta-analysis on the Effect of Reperfusion Use of a Single
High Dose of ATG-F on the Incidence of Delayed Graft
Function. Four articles met the standards for studying the
effect on the incidence of delayed graft function (DGF),
including 140 patients in the experimental group and 126
patients in the control group. A random effect model was
used for the analysis. The results of the meta-analysis
showed that the RR was 1.02 after combining and the
95% CI was 0.64e1.60 (Fig 7). The results suggested that
the combined difference had no statistical signiﬁcance,
that is, the presurgical use of a single large dose of
ATG-F had no obvious effect on the incidence of DGF
compared to that in the control group.DISCUSSION
ATG-F is a selective immune suppressor targeting human
T-lymphocytes. The immune suppression mechanism of
ATG-F has been suggested to be complement-mediated
cytotoxicity that directly kills activated T-lymphocytes or
induces the expression of Fas ligand on the surface of
T-lymphocytes and enhances the sensitivity of apoptosis.
In this way, expanded clonal T-lymphocytes can be
eliminated [14,15].
In a previous study, although ATG-F reduced the inci-
dence of AR reaction, it also caused serious side effects in
the kidney recipients, such as mortality caused by cardio-
vascular and infectious events and a signiﬁcantly increased
incidence of advanced-stage malignant tumors [5].Fig 4. Meta-analysis on the effect of the reperfusion use of a single h
incidence of cytomegalovirus infection.Therefore, Kaden et al proposed a treatment plan to move
the induction therapy with ATG from the postsurgical
period to the presurgical period with a single large dose [6].
Kaden et al reported that the application of a referfusion
single high dose of ATG-F induction therapy could increase
the survival rates of both the kidney grafts and patients
compared to those achieved with routine triple drug main-
tenance therapy [16]. However, this was a retrospective
study. To conﬁrm the efﬁcacy and safety of a reperfusion
single large dose of ATG-F, this study reported the meta-
analyses of RCTs involving the application of a reperfu-
sion single high dose of ATG-F in kidney transplantation in
China and abroad.
The results of the meta-analysis demonstrated that the
reperfusion use of a single high dose of ATG-F could sta-
tistically reduce the incidence of AR in kidney trans-
plantation (RR ¼ 0.50, 95% CI ¼ 0.35e0.71, P ¼ .0001).
Namely, reperfusion use of a single high dose of ATG-F
could signiﬁcantly reduce the incidence of AR. Several tri-
als also reached the same conclusion [10,11,17,18], because
the AR reaction is closely correlated with T cells. After the
reperfusion injection of a high dose of ATG, the elimination
of T cells can be observed before the renal graft vascular
anastomoses are complete within 5 days after surgery [10].
However, the reperfusion application of ATG-F at a single
high dose showed no signiﬁcant differences in the incidences
of infections (such as UTI and CMV infection) or the 1-year
survival rates of the kidney grafts and patients compared to
those of the control group. Kaden et al suggested that anyigh dose of antieT-lymphocyte globulin Fresenius (ATG-F) on the
Fig 5. Meta-analysis on the effects of the reperfusion use of a single high dose of antieT-lymphocyte globulin Fresenius (ATG-F) on the
1-year graft survival rate in kidney transplantation.
SAFETY/EFFICACY OF ATG-F IN KIDNEY TRANSPLANTATION 2021immunosuppressive treatment must be balanced between
reducing AR reaction and increasing infection incidence. By
comparing the number of lymphocytes, T-cell subset
numbers, and frequency of ATG-Feassociated side effects,
Kaden et al discovered that a presurgical single large dose of
ATG-F could properly balance rejection and infection to
avoid oversuppression [16].
Figure 6 shows that the incidence of DGF in the ATG-F
group (50/140) was lower than that in the control group
(46/126); however, no signiﬁcant difference was identiﬁed
between the two groups (P ¼ .95). For the RCTs in the four
articles used to study DGF, only Kyllonen et al suggested
that the ATG-F group could reduce the incidence of DGF.
The other three articles suggested that ATG-F had no
obvious effect on DGF. The study by Van den Hoogen et al
was weighted relatively heavily in our conclusion measure
(37.2%); in that study, ATG-F showed only limited effects
on the T-cells in DGF pathology as well as on the recovery
of acute tubular necrosis. It was also suggested that the
positive effect of ATG-F on the reduction of DGF could be
cancelled by its negative effects (such as infection). In
addition, DGF could also be correlated with other factors,
such as ischemia-reperfusion injury, and the varied immu-
nosuppressive doses [13].
Based on the meta-analysis, we discovered that the use of
a single high dose (9 mg/kg) of ATG-F before the surgery
could effectively reduce the incidence of postsurgical AR
response without affecting the occurrence of infections, theFig 6. Meta-analysis on the effect of the reperfusion use of a single h
1-year patient survival rate.survival rates of kidney grafts and patients, and the inci-
dence of DGF. In addition, compared to the application of
ATG-F at other doses, a single large dose is more
economical [9]. The results suggested that a reperfusion
single high dose of ATG-F represents a better value in
terms of reducing rejection reactions.
Compared to the number of kidney transplantations
performed worldwide, the ﬁve RCTs discussed in this study
included only a small number of cases (346 patients) and
lacked global representation. In the included trials, some
patients were maintained with cyclosporin A, azathioprine,
and prednisolone/prednisone [9e11], whereas the others
received tacrolimus, mycophenolate mofetil, and predniso-
lone/prednisone [12,13]. These combinations are well
established as being associated with signiﬁcantly different
acute rejection rates, as well as heterogeneity. Because the
maintenance therapy and the sources of donor kidney used
were not the same in the included trials, it is more accurate
to use a random effects model to analyze the limited trials.
As we were limited by the indexes of the studies in the
original trial, we could perform meta-analyses only on the
incidence of infection based on certain types of conditions,
including UTI and CMV infection. Therefore, this study
could not fully provide complete infection conditions after
kidney transplantation. In this study, only RCTs were
included; descriptive studies were excluded. In addition, the
included RCTs were from various periods and trans-
plantation facilities. The different presurgical assessments,igh dose of antieT-lymphocyte globulin Fresenius (ATG-F) on the
Fig 7. Meta-analysis on the effect of the reperfusion use of a single high dose of antieT-lymphocyte globulin Fresenius (ATG-F) on the
incidence of delayed graft function.
2022 DU, WANG, SUN ET ALdoses of immunosuppressive agents, and hormone with-
drawal strategies for the recipients resulted in unavoidable
clinical heterogeneity. In sum, it is necessary to study more
clinical trials with large samples from multiple facilities with
high quality and high speciﬁcity to obtain more reliable
conclusions.REFERENCES
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